RenovaCare touts data from 44-patient SkinGun burn treatment retrospective analysis

RenovaCare today released results from a retrospective analysis of 44 patients with severe second-degree wide-area burn injuries who were treated with the technology underlying the company’s SkinGun and CellMist system.

Results from the analysis were published in the peer-reviewed journal Burns, the company said.

“Treated patients presented with a variety of burn wound etiologies and a wide range of TBSA (Total Burn Surface Area). Overall clinical results were very satisfying,” study authors wrote in a press release.

The 44 patients in the analysis were treated through a method which involved isolating and spraying the patients’ skin stem cells onto burn wounds, which RenovaCare said uses technology its SkinGun and CellMist system are based off of.

Patients in the analysis were treated for deep partial-thickness burns, including gas and chemical explosions and electrical, gasoline, hot water and tar scalding burns, RenovaCare said.

According to data from the published analysis, use of the technology on such burn wounds “can achieve rapid wound re-epithelialization, particularly in large wounds.” Average days to healing and discharge in the analysis were low, regardless of the severity or size of the wound, the company said.

“This data is especially compelling because patients were successfully treated for a broad spectrum of burn injuries and vast burn surface areas. Importantly, patients had very short hospital stays, which, we believe could deliver a better healing experience for patients and lower costs for hospitals and insurance providers. The clinical outcomes and minimal hospital stays for severe burn patients published in this article supports our conviction to bring our SkinGun technology to market as quickly as possible. Presently, we’re finalizing the requisite documentation for filing with the FDA to demonstrate the safety of our approach for treating wounds using a patient’s own skin cells,” RenovaCare prez & CEO Thomas Bold said in a prepared statement.

Last October, RenovaCare said it raised $2.3 million in a new direct offering to support its SkinGun technology.

The post RenovaCare touts data from 44-patient SkinGun burn treatment retrospective analysis appeared first on MassDevice.

from MassDevice http://ift.tt/2DNCoaJ